These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1452 related articles for article (PubMed ID: 26231288)

  • 1. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
    Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
    Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
    Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials.
    Panettieri RA; Sjöbring U; Péterffy A; Wessman P; Bowen K; Piper E; Colice G; Brightling CE
    Lancet Respir Med; 2018 Jul; 6(7):511-525. PubMed ID: 29792288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
    Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
    Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
    Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
    Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.
    Hanania NA; Korenblat P; Chapman KR; Bateman ED; Kopecky P; Paggiaro P; Yokoyama A; Olsson J; Gray S; Holweg CT; Eisner M; Asare C; Fischer SK; Peng K; Putnam WS; Matthews JG
    Lancet Respir Med; 2016 Oct; 4(10):781-796. PubMed ID: 27616196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Russell RJ; Chachi L; FitzGerald JM; Backer V; Olivenstein R; Titlestad IL; Ulrik CS; Harrison T; Singh D; Chaudhuri R; Leaker B; McGarvey L; Siddiqui S; Wang M; Braddock M; Nordenmark LH; Cohen D; Parikh H; Colice G; Brightling CE;
    Lancet Respir Med; 2018 Jul; 6(7):499-510. PubMed ID: 29793857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials.
    Kerstjens HA; Casale TB; Bleecker ER; Meltzer EO; Pizzichini E; Schmidt O; Engel M; Bour L; Verkleij CB; Moroni-Zentgraf P; Bateman ED
    Lancet Respir Med; 2015 May; 3(5):367-76. PubMed ID: 25682232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
    Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
    Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.
    Wechsler ME; Ford LB; Maspero JF; Pavord ID; Papi A; Bourdin A; Watz H; Castro M; Nenasheva NM; Tohda Y; Langton D; Cardona G; Domingo C; Park HS; Chapman KR; Mao X; Zhang Y; Khan AH; Deniz Y; Rowe PJ; Kapoor U; Khokhar FA; Mannent LP; Ruddy M; Laws E; Amin N; Hardin M
    Lancet Respir Med; 2022 Jan; 10(1):11-25. PubMed ID: 34597534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
    Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
    Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma.
    Oh CK; Leigh R; McLaurin KK; Kim K; Hultquist M; Molfino NA
    Respir Res; 2013 Sep; 14(1):93. PubMed ID: 24050312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.
    Rabe KF; Celli BR; Wechsler ME; Abdulai RM; Luo X; Boomsma MM; Staudinger H; Horowitz JE; Baras A; Ferreira MA; Ruddy MK; Nivens MC; Amin N; Weinreich DM; Yancopoulos GD; Goulaouic H
    Lancet Respir Med; 2021 Nov; 9(11):1288-1298. PubMed ID: 34302758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
    Castro M; Corren J; Pavord ID; Maspero J; Wenzel S; Rabe KF; Busse WW; Ford L; Sher L; FitzGerald JM; Katelaris C; Tohda Y; Zhang B; Staudinger H; Pirozzi G; Amin N; Ruddy M; Akinlade B; Khan A; Chao J; Martincova R; Graham NMH; Hamilton JD; Swanson BN; Stahl N; Yancopoulos GD; Teper A
    N Engl J Med; 2018 Jun; 378(26):2486-2496. PubMed ID: 29782217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma.
    Gallagher A; Edwards M; Nair P; Drew S; Vyas A; Sharma R; Marsden PA; Wang R; Evans DJ
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD012929. PubMed ID: 34664263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.